» Articles » PMID: 33722383

Animal Models of Preeclampsia: Investigating Pathophysiology and Therapeutic Targets

Overview
Publisher Elsevier
Date 2021 Mar 16
PMID 33722383
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Animal models have been critical in investigating the pathogenesis, mediators, and even therapeutic options for a number of diseases, including preeclampsia. Preeclampsia is the leading cause of maternal and fetal morbidity and mortality worldwide. The placenta is thought to play a central role in the pathogenesis of this disease because it releases antiangiogenic and proinflammatory factors into the maternal circulation, resulting in the maternal syndrome. Despite the deleterious effects preeclampsia has been shown to have on the mother and baby during pregnancy and postpartum, there is still no effective treatment for this disease. Although clinical studies in patients are crucial to identify the involvement of pathogenic factors in preeclampsia, there are obvious limitations that prevent detailed investigation of the quantitative importance of time-dependent mechanisms involved in this syndrome. Animal models allow investigators to perform proof-of-concept studies and examine whether certain factors found in women with preeclampsia mediate hypertension and other manifestations of this disease. In this brief review, we summarize some of the more widely studied models used to investigate pathophysiological mechanisms that are thought to be involved in preeclampsia. These include models of placental ischemia, angiogenic imbalance, and maternal immune activation. Infusion of preeclampsia-related factors into animals has been widely studied to understand the specific mediators of this disease. These models have been included, in addition to a number of genetic models involved in overexpression of the renin-angiotensin system, complement activation, and trophoblast differentiation. Together, these models cover multiple mechanisms of preeclampsia from trophoblast dysfunction and impaired placental vascularization to the excess circulating placental factors and clinical manifestation of this disease. Most animal studies have been performed in rats and mice; however, we have also incorporated nonhuman primate models in this review. Preclinical animal models not only have been instrumental in understanding the pathophysiology of preeclampsia but also continue to be important tools in the search for novel therapeutic options for the treatment of this disease.

Citing Articles

Complement 3 and 4 impact in osteoarthritis.

Wang L Biomark Med. 2025; 19(3):81-90.

PMID: 39893562 PMC: 11792862. DOI: 10.1080/17520363.2024.2409062.


Development of immune-derived molecular markers for preeclampsia based on multiple machine learning algorithms.

Wang Z, Cheng L, Li G, Cheng H Sci Rep. 2025; 15(1):1767.

PMID: 39815029 PMC: 11736010. DOI: 10.1038/s41598-025-86442-9.


Distinct phenotypes in the preeclamptic-like mouse model induced by adenovirus carrying sFlt1 and recombinant sFlt1 protein.

Wei Y, Tian H, Wei X, Zhang A, Wei M, Wang R Eur J Med Res. 2024; 29(1):642.

PMID: 39741314 PMC: 11689622. DOI: 10.1186/s40001-024-02223-6.


Research Hotspots and Thematic Trends in the Management of Preeclampsia: A Bibliometric Analysis from 2000 to 2022.

Shen X, Tao Y, Wang Y, Obore N, Yu H Reprod Sci. 2024; 32(3):815-824.

PMID: 39741168 DOI: 10.1007/s43032-024-01773-8.


Intrauterine growth-restricted pregnant rats, from placental ischemic dams, display preeclamptic-like symptoms: A new rat model of preeclampsia.

Smith J, Powell M, Cromartie W, Smith S, Jones K, Castillo A Physiol Rep. 2024; 12(21):e70112.

PMID: 39482843 PMC: 11527824. DOI: 10.14814/phy2.70112.


References
1.
Wang L, Zhang Y, Qu H, Xu F, Hu H, Zhang Q . Reduced ELABELA expression attenuates trophoblast invasion through the PI3K/AKT/mTOR pathway in early onset preeclampsia. Placenta. 2019; 87:38-45. DOI: 10.1016/j.placenta.2019.08.077. View

2.
Ramesar S, Mackraj I, Gathiram P, Moodley J . Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley rats. Eur J Obstet Gynecol Reprod Biol. 2011; 157(2):136-40. DOI: 10.1016/j.ejogrb.2011.03.005. View

3.
Makris A, Yeung K, Lim S, Sunderland N, Heffernan S, Thompson J . Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates. Hypertension. 2016; 67(6):1263-72. PMC: 4867111. DOI: 10.1161/HYPERTENSIONAHA.116.07286. View

4.
LaMarca B, Parrish M, Wallace K . Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia. Gend Med. 2012; 9(3):139-46. PMC: 3483641. DOI: 10.1016/j.genm.2012.03.001. View

5.
Gatford K, Andraweera P, Roberts C, Care A . Animal Models of Preeclampsia: Causes, Consequences, and Interventions. Hypertension. 2020; 75(6):1363-1381. DOI: 10.1161/HYPERTENSIONAHA.119.14598. View